- Home
- DBVT vs ASST Comparison
DBVT vs ASST Comparison
Compare DBVT & ASST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DBVT | ASST |
|---|---|---|
| Founded | 2002 | 2020 |
| Country | France | United States |
| Employees | 117 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 998.7M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | DBVT | ASST |
|---|---|---|
| Price | $20.70 | $8.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $31.75 | $30.00 |
| AVG Volume (30 Days) | 477.4K | ★ 5.3M |
| Earning Date | 10-28-2025 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $5,502,000.00 | ★ $5,512,106.00 |
| Revenue This Year | $1,768.71 | N/A |
| Revenue Next Year | $1,028.88 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 125.01 |
| 52 Week Low | $3.82 | $7.57 |
| 52 Week High | $26.19 | $157.80 |
Technical Indicators
Market Signals| Indicator | DBVT | ASST |
|---|---|---|
| Relative Strength Index (RSI) | 51.93 | 69.12 |
| Support Level | $20.85 | $7.57 |
| Resistance Level | $24.65 | $12.25 |
| Average True Range (ATR) | 1.47 | 0.58 |
| MACD | -0.24 | 0.73 |
| Stochastic Oscillator | 33.33 | 64.59 |
Price Performance
Historical ComparisonAbout DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
About ASST Asset Entities Inc. Class B
Strive Inc is engaged in providing investment advisory, wealth management, and consulting services through its subsidiary. Its objectives is to (i) accumulate Bitcoin; (ii) increase Bitcoin-per-share; and (iii) outperform Bitcoin over the long run by deploying both beta Bitcoin treasury accumulation strategies and alpha investment strategies with the goal of beating Bitcoin's investment performance as the hurdle rate.